Panel Votes to Keep Strong Warning on Smoking-Cessation Drug

An FDA advisory panel rejected an effort by Pfizer to remove boxed warnings of neuropsychiatric dangers on the label for Chantix, the company’s smoking-cessation drug.



from WSJ.com: US Business http://ift.tt/ZwMRBY

via IFTTT